Cerebrolysin: sourcing, documentation and price

Cerebrolysin is the formal name of a multimodal neuropeptide preparation derived from porcine brain, supplied as a sterile solution for laboratory research use. It is not a single molecular entity: the evidence block for this page does not give a sequence, a molecular formula or a molecular weight, and none should be assumed. The preparation is studied as a mixture of low-molecular-weight neuropeptides and free amino acids, and it is handled in the literature as a class of neurotrophic and neuroprotective research material rather than as a defined receptor ligand. Where a catalogue lists it, the listing is a research reagent, not a therapeutic product.

The work on this page centres on neurotrophic and neuroprotective signalling relevant to cerebral endothelial integrity, blood-brain barrier function and post-ischemic recovery, with the endothelial permeability and tight-junction protein literature providing the clearest mechanistic anchor in the evidence supplied here [4].

Research Studies

Cerebrolysin and endothelial permeability in an in vitro cerebral endothelial cell model

An in vitro endothelial permeability assay tested whether exosomes released by cerebral endothelial cells (CECs) after Cerebrolysin treatment, termed Cerebro-Exos, could restore barrier function in dysfunctional CECs. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes from untreated CECs (Naïve-Exos); Cerebro-Exos were highly enriched in metabolic and tight junction related proteins. Cerebro-Exos had a superior effect compared with Naïve-Exos on restoring CEC integrity impaired by fibrin and tissue plasminogen activator [4]. This is an in vitro finding and does not establish an effect in animals or in humans.

Cerebrolysin and extended-window endovascular thrombectomy in acute ischemic stroke

A multicenter randomized clinical trial is evaluating whether Cerebrolysin given after successful extended-window endovascular thrombectomy reduces brain tissue injury and supports recovery. The trial addresses a recognised problem: endovascular thrombectomy can benefit selected patients treated 6 to 24 hours after stroke onset, but some patients remain disabled even when the blocked artery is successfully reopened, and ongoing injury to brain tissue, small blood vessels and the blood-brain barrier may contribute to that incomplete recovery [1]. The evidence block describes the trial as ongoing; no outcome data are reported here.

Cerebrolysin and 12-month functional outcomes after endovascular thrombectomy

A propensity-matched cohort study reported 12-month functional outcomes for Cerebrolysin after endovascular thrombectomy in stroke [8]. The evidence block supplies the abstract title only, without numerical results, so no effect size or direction of effect can be stated on this page.

Cerebrolysin and basilar artery occlusion after mechanical thrombectomy

A case report described a 67-year-old woman with multiple vascular risk factors who presented with acute basilar artery occlusion and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction grade 3), with adjunctive Cerebrolysin administered subsequently. Rapid neurological improvement was observed within 24 hours, with the National Institutes of Health Stroke Scale score decreasing from 7 to 2, followed by complete neurological recovery (NIHSS 0) [2]. This is a single case report; it is not controlled evidence and cannot support a general claim of efficacy.

Cerebrolysin and post-stroke Wernicke's aphasia with speech-language therapy

A case report described a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis following an ischemic stroke. Despite timely thrombolysis and mechanical thrombectomy she experienced significant neurological deficits; early multidisciplinary rehabilitation combined with a 10-day course of Cerebrolysin was administered [3]. The evidence block does not report the outcome values for this case, so no recovery claim is made here. The report is a single case and is not controlled evidence.

Cerebrolysin combined with speech therapy in nonfluent aphasia after ischemic stroke

A meta-analysis abstract reported on the effect of Cerebrolysin combined with speech therapy on nonfluent aphasia recovery after ischemic stroke [6]. The evidence block provides the abstract title only; no pooled estimate, confidence interval or patient count is available, so no quantitative statement can be made.

Cerebrolysin as an add-on in virtual reality neurorehabilitation in acute stroke

A conference abstract reported on virtual reality neurorehabilitation in acute stroke patients and the add-on effect of Cerebrolysin [7]. The evidence block supplies the abstract title only, without results, and no effect can be reported from it.

Cerebrolysin and very early short-course use after tenecteplase and mechanical thrombectomy

A case report described an 88-year-old woman treated with a very early short course of Cerebrolysin after tenecteplase and mechanical thrombectomy. The report notes that despite high recanalization rates with mechanical thrombectomy, large-vessel occlusion stroke results in death or dependency in over half of patients, and it frames Cerebrolysin as a multimodal neuropeptide preparation that may attenuate ischemia-reperfusion injury and support early neurorehabilitation [9]. This is a single case report and is not controlled evidence.

Cerebrolysin and neuropathic pain with blood-spinal cord barrier breakdown in a nanoparticle intoxication model

A retraction note concerns a study that had reported Cerebrolysin attenuating exacerbation of neuropathic pain, blood-spinal cord barrier breakdown and cord pathology following chronic intoxication with engineered silver, copper or aluminium nanoparticles of 50 to 60 nm [5]. Because the article has been retracted, its findings should not be relied upon, and it is listed here only to document the state of the record.

Comparison of study designs in the evidence block

Documentation a laboratory buyer should expect

Because the evidence block does not provide a sequence, formula or molecular weight for this preparation, a buyer cannot verify identity against a published structure. What can be documented is the lot-specific certificate of analysis, the stated concentration and volume, the storage conditions, and the supplier's statement of origin and handling. Purity and composition claims for a peptide mixture are supplier-defined; the peer-reviewed literature cited here does not supply a reference standard against which a lot can be checked.

• Certificate of analysis for the specific lot.
• Stated concentration, volume and buffer composition.
• Storage and shipping conditions.
• Statement of research-use-only status.

Price and sourcing considerations

Price for a research-grade neuropeptide preparation is set by lot size, concentration, documentation and cold-chain handling rather than by any clinical claim. The evidence block contains no pricing data, and none is asserted here. Buyers comparing suppliers should compare the documentation package first, because the analytical identity of a mixture cannot be confirmed from a catalogue number alone. Where a study is cited in support of a listing, check whether that study is a controlled trial, a case report, an in vitro assay or a retraction note; the table above shows how widely those differ within a single evidence set.

Limits of the evidence

Most of the human material in the evidence block is case-report level, and the controlled human evidence is either ongoing or reported only as an abstract title without values [1][6][7][8]. The mechanistic work is in vitro [4]. One study in the set has been retracted [5], and three further items are retraction notes or reference-only records [10][11][12]. No claim on this page should be read as an established clinical effect.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is medical advice or a recommendation for personal use.

Sources

• [1] Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy — https://clinicaltrials.gov/study/NCT06339411
• [2] Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report — https://europepmc.org/article/PMC/PMC13474398
• [3] Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report — https://europepmc.org/article/PMC/PMC13474394
• [4] Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability — https://europepmc.org/article/PMC/PMC13205112
• [5] Retraction Note: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-Spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles — https://europepmc.org/article/PMC/PMC13179879
• [6] ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE — https://europepmc.org/article/PMC/PMC13146077
• [7] ABSTRACT NUMBER: ESOC2026A822 VIRTUAL REALITY NEUROREHABILITATION IN ACUTE STROKE PATIENTS AND THE ADD-ON EFFECT OF CEREBROLYSIN — https://europepmc.org/article/PMC/PMC13145624
• [8] ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT — https://europepmc.org/article/PMC/PMC13146562
• [9] Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report — https://pubmed.ncbi.nlm.nih.gov/42666484/
• [10] Retraction: Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in AβPP Transgenic Mice — https://pubmed.ncbi.nlm.nih.gov/42015030/
• [11] Retraction Note to: Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease — https://pubmed.ncbi.nlm.nih.gov/41920231/
• [12] Retraction Note: Neurotrophic effects of Cerebrolysin in the Mecp2^308/Y transgenic model of Rett syndrome — https://pubmed.ncbi.nlm.nih.gov/41874695/